<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02972684</url>
  </required_header>
  <id_info>
    <org_study_id>RC16_0009</org_study_id>
    <nct_id>NCT02972684</nct_id>
  </id_info>
  <brief_title>Cost-Utility Analysis of Management of Peri Operative Haemorrhage Following Cardiac Surgery With Cardiopulmonary Bypass</brief_title>
  <acronym>IMOTEC</acronym>
  <official_title>Cost-Utility Analysis of Management of Peri Operative Haemorrhage Following Cardiac Surgery Using Conventional Blood Coagulation Tests or Thrombo-elastographic Point of Care Test - IMOTEC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peri operative haemorrhage following cardio Pulmonary Bypass may occur in 5 to 10% of cardiac&#xD;
      surgical interventions.&#xD;
&#xD;
      Treatment of such complication often necessitates various combinations therapeutic&#xD;
      intervention including allogenic blood products administration, drug use and/or surgical&#xD;
      intervention. All are expensive treatment and decision making is guided by patient clinical&#xD;
      status and biological tests of the haemostatic function.&#xD;
&#xD;
      A key point is the time frame of the clinical process. Therapeutic choices have to be done as&#xD;
      fast as possible to minimize bleeding consequences on patient haemodynamic and physiological&#xD;
      status. Conventional coagulation test results availability time usually exceed 45' after&#xD;
      blood drawing. In such situation, the results may not reflect precisely the coagulation&#xD;
      system current state. This downside is often counterbalanced by clinicians empirical choices&#xD;
      preceding lab test results knowledge that may conduct to inappropriate treatment, blood&#xD;
      product overuse and undue expense.&#xD;
&#xD;
      Viscoelastic point of care test may compensate for the limitations of conventional&#xD;
      coagulation tests. In perioperative haemorrhage, faster and more precise information about&#xD;
      haemostatic function may help for more accurate therapeutic choices.&#xD;
&#xD;
      The IMOTEC study aims to compare haemorrhage management following cardiac surgery using&#xD;
      conventional blood coagulation tests or thrombo-elastogaphic point of care test.&#xD;
&#xD;
      Primary endpoint is a cost utility analysis of the technology and secondary endpoints include&#xD;
      blood component transfusion, postoperative bleeding , thoracic re-intervention, postoperative&#xD;
      infection (any cause), organ failure, in hospital length of stay and death.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research is a real life, prospective, single blinded stepped wedge randomized study.&#xD;
&#xD;
      Inclusion after informed consent of adult patient having cardio-vascular surgical procedure&#xD;
      using cardiopulmonary bypass and meeting inclusion criterion &quot;bleeding&quot;.&#xD;
&#xD;
      After meeting inclusion criterion patients are managed either using conventional blood&#xD;
      coagulation tests or using thrombo-elastometry POC test and predefined therapeutic&#xD;
      interventions described in a specific algorithm.&#xD;
&#xD;
      Other elements of patient clinical management follow usual center standard care .&#xD;
&#xD;
      Follow up of EQ-5D and clinical evaluations are performed at one , 6 and 12 months after&#xD;
      inclusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2017</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cost-utility ratio</measure>
    <time_frame>one year</time_frame>
    <description>incremental cost per incremental life year and incremental costs per incremental QALY</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incremental cost effectiveness ratio</measure>
    <time_frame>one year</time_frame>
    <description>incremental cost effectiveness ratio : difference in costs divided by the difference in mortality and serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rates</measure>
    <time_frame>one year</time_frame>
    <description>Parameters followed during hospitalization are: volume of postoperative bleeding, allogeneic blood product transfusion, blood cell count, postoperative complications: surgical reexploration, acute kidney injury, need for renal replacement therapy, organ failure, acquired infections, mechanical ventilation duration, intensive care, and in hospital length of stay, death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rates</measure>
    <time_frame>one year</time_frame>
    <description>The major complications that can occur within 12 months are: death, cardio-thoracic surgical intervention, acute kidney injury, need for renal replacement therapy, any serious illness diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation survey</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation survey regarding the context and the parameters that impacted the physician's decision, which will be used a sub-group of 100 patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The location of the Thrombo-elastometry POC testing</measure>
    <time_frame>three years</time_frame>
    <description>The location of the Thrombo-elastometry POC testing (operative room or laboratory)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1098</enrollment>
  <condition>C.Surgical Procedure; Cardiac</condition>
  <condition>Blood Transfusion</condition>
  <condition>Blood Coagulation Disorders</condition>
  <condition>Bypass, Cardiopulmonary</condition>
  <condition>Hemostatic</condition>
  <arm_group>
    <arm_group_label>Conventional coagulation management</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>management of perioperative haemorrhage following cardiac surgery using conventional blood coagulation tests.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thrombo-elastometry POC testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>management of perioperative haemorrhage following cardiac surgery using the thrombo-elastometry point of care test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thrombo-elastometry POC testing</intervention_name>
    <description>Use of thrombo-elastometry point of care test and algorithm guided predetermined intervention during peri operative haemorrhage</description>
    <arm_group_label>Thrombo-elastometry POC testing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Pre-Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients over 18 years old scheduled for elective or urgent cardiac surgery&#xD;
             using cardiopulmonary bypass .&#xD;
&#xD;
          -  Patient informed written consent (non-opposition to data use) or person of trust or&#xD;
             family member information .&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        Blood Coagulation test sampling indication for intra or post-operative bleeding defined as&#xD;
        follow:&#xD;
&#xD;
          1. intra-operative post CPB bleeding; evaluation more than 10min after heparin reversal&#xD;
             by protamin.&#xD;
&#xD;
               -  Clinically significant bleeding judged on surgeon and anesthesiologist consensual&#xD;
                  point of view&#xD;
&#xD;
               -  Sternal closure delay&#xD;
&#xD;
               -  Chest tube bleeding exceeding 50ml in 10min or more than 1ml/kg in 30min&#xD;
                  (2ml/kg/h)&#xD;
&#xD;
          2. Postoperative period , evaluation in post operative care environment after 30min&#xD;
             stabilization period&#xD;
&#xD;
               -  Chest tube bleeding exceeding 50ml in 10min or more than 1ml/kg in 30min&#xD;
                  (2ml/kg/h)&#xD;
&#xD;
               -  Patient requiring surgical re-exploration for diagnosed or suspected pericardial&#xD;
                  effusion or surgical site bleeding requiring surgical hemostatic intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known congenital bleeding disorder&#xD;
&#xD;
          -  Redo surgery for patient previously included in the study&#xD;
&#xD;
          -  Implantation of Cardiac support device, Extra Corporeal Membrane Oxygenation (ECMO)&#xD;
             Extra Corporeal Life support (ECLS), uni or bi-ventricular artificial hearts.&#xD;
&#xD;
          -  Indication for post-CPB ECMO or ECLS&#xD;
&#xD;
          -  blood transfusion refusal&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  patients under 18 years old&#xD;
&#xD;
          -  Adult patient under guardianship, trusteeship or safeguard justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand Rozec, PUPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bordeaux University hospital</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dijon University Hospital</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lille University hospital</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille AP-HM La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nancy University Hospital</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP, La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HEGP, Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Etienne University Hospital</name>
      <address>
        <city>Saint-Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strasbourg Universtiy Hospital</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toulouse University Hospital</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tours University Hospital</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Rigal JC, Boissier E, Lakhal K, Riche VP, Durand-Zaleski I, Rozec B. Cost-effectiveness of point-of-care viscoelastic haemostatic assays in the management of bleeding during cardiac surgery: protocol for a prospective multicentre pragmatic study with stepped-wedge cluster randomised controlled design and 1-year follow-up (the IMOTEC study). BMJ Open. 2019 Nov 5;9(11):e029751. doi: 10.1136/bmjopen-2019-029751.</citation>
    <PMID>31694845</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2016</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiopulmonary Bypass</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>blood transfusion</keyword>
  <keyword>Point-of-care test</keyword>
  <keyword>health economics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

